Zelebrudomide
Small molecule
Also known as NX-2127
Evidence outlook · program status
Discontinued (2026-08), as a strategic decision by the sponsor
Nurix discontinued further clinical development of zelebrudomide (NX-2127) in a strategic prioritization of its oncology portfolio. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04830137 NCT04830137 · Relapsed/Refractory B-Cell Malignancies Registry: NCT04830137 | 1 | Number of Participants with Protocol Specified Dose-Limiting Toxicities (Up to 24 months); To establish the MTD and/or recommended Phase 1b dosage(s) of NX-2127 (Up to 24 months); To evaluate the clinical activity of NX-2127 at the recommended Phase 1b dosage(s) based on overall response rate (ORR) as assessed by the Investigator (Up to 4 years); Number of Participants with Adverse Events and Clinical Laboratory Abnormalities (Up to 5 years) 2026-05 | In progress: primary completion was expected 1 May 2026; results not posted | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.